Big data with heart, for psychiatric disorders

Heart rate variability can be used to monitor psychiatric Read more

Unlocking schizophrenia biology via genetics

A genetic risk factor for schizophrenia could be a key to unlock the biology of the complex Read more

Brain circuitry linked to social connection and desire to cuddle

Just like humans, prairie voles are capable of consistently forming social bonds with mating partners, a rare trait in the animal Read more

Emory Chemical Biology Discovery Center

Anticancer strategy: expanding what is druggable

Scientists at Winship Cancer Institute, Emory University have identified compounds that stop two elusive anticancer targets from working together. In addition to striking two birds with one stone, this research could expand the envelope of what is considered “druggable.”

fx1-1Many of the proteins and genes that have critical roles in cancer cell growth and survival have been conventionally thought of as undruggable. That’s because they’re inside the cell and aren’t enzymes, for which chemists have well-developed sabotage strategies.

In a twist, the potential anticancer drugs described in Cancer Cell disable an interaction between a notorious cancer-driving protein, MDM2, and a RNA encoding a radiation-resistance factor, XIAP.

The compounds could be effective against several types of cancer, says senior author Muxiang Zhou, MD, professor of pediatrics (hematology/oncology) at Emory University School of Medicine and Aflac Cancer and Blood Disorders Center.

In the paper, the compounds show activity against leukemia and neuroblastoma cells in culture and in mice, but a fraction of many other cancers, such as breast cancers (15 percent) and sarcoma (20 percent), show high levels of MDM2 and should be susceptible to them.

Read more

Posted on by Quinn Eastman in Cancer 1 Comment